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OBJECTIVES The aim of this study was to discern a target range of anticoagulation for enoxaparin during
percutaneous coronary intervention (PCI) as measured by the Rapidpoint ENOX (Pharma-
netics Inc., Morrisville, North Carolina), a new point-of-care test.
BACKGROUND In the U.S., enoxaparin has been used in only a small proportion of PCI procedures, partly
because a rapid enoxaparin-specific assay was unavailable.
METHODS We analyzed data from 445 enrolled patients receiving subcutaneous or intravenous
enoxaparin in a prospective, multicenter study. Serial anticoagulation measurements and
clinical outcomes were recorded.
RESULTS The in-hospital composite occurrence of death, myocardial infarction, and urgent target
vessel revascularization was 5.4%, and Thrombolysis In Myocardial Infarction (TIMI) major
bleeding, minor bleeding, and any reported bleeding occurred in 0.2%, 1.3%, and 7.9% of
patients, respectively. No significant association between procedural ENOX times and
ischemic events was observed (p  0.222), although the event rate was 4.0% among those
with ENOX times between 250 to 450 s versus 7.2% for those outside this range (p 0.134).
Increasing ENOX time at sheath removal was correlated with any bleeding (p  0.010) with
a 1% increase for every 30-s rise.
CONCLUSIONS Ischemic events were infrequent, and the rate appeared lowest in the mid-range of ENOX
times. Bleeding events increased with increasing ENOX times. These observations, combined
with a suggested procedural anti-Xa level of 0.8 to 1.8 IU/ml, translate into a recommended
ENOX time range of 250 to 450 s for PCI and 200 to 250 s for sheath removal. (J Am
Coll Cardiol 2003;42:1132–9) © 2003 by the American College of Cardiology Foundation
Several large-scale clinical trials have demonstrated the
superiority of low-molecular-weight heparin (LMWH)
over unfractionated heparin (UFH) for medical treatment of
acute coronary syndromes (ACS), resulting in the adoption
of LMWH as a standard of care (1). The shift from UFH
to fractionated heparin, such as enoxaparin, has been slower
in some medical centers where a large proportion of ACS
patients transition to percutaneous coronary intervention
(PCI), partly because a rapid assay for monitoring enoxapa-
rin has not been available. Systemic anticoagulation with
UFH has been an integral part of PCI ever since the proce-
dure’s inception, and the activated clotting time (ACT) is
routinely used to help balance the thrombotic and hemorrhagic
risks associated with procedural anticoagulation.
A rapid point-of-care assay for enoxaparin (Rapidpoint
ENOX, Pharmanetics Inc., Morrisville, North Carolina)
has been recently developed and was approved by the U.S.
Food and Drug Administration (FDA) (2). The purpose of
this study was to measure ENOX times and anti-factor Xa
activity levels, and to compare these measures with ischemic
and hemorrhagic events observed in patients undergoing
PCI. The primary objective was to discern a desirable range
for procedural anticoagulation and separately to determine a
threshold level below which hemostasis can be achieved for
vascular access sheath removal.
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METHODS
Study population. Patients were eligible for enrollment if
they were to undergo elective intent-to-stent PCI and had
received at least two doses of subcutaneous (SC) enoxaparin
(1.0 mg/kg) within the previous 24 h or had not received
antithrombin therapy within 8 h immediately prior to PCI
and were to be treated with intravenous (IV) enoxaparin
(0.75 to 1.0 mg/kg) for the PCI procedure. Patients were
excluded if they had ongoing ST-segment elevation myo-
cardial infarction (MI), recent (24 h) treatment with
fibrinolytic therapy, a baseline ACT 140 s, a prothrombin
time international normalized ratio 1.5, a history of
heparin-induced thrombocytopenia, or a contraindication to
aspirin, clopidogrel, or enoxaparin. The study enrolled a
total of 673 patients. During enrollment, the FDA approved
the ENOX test and required a change in technique. The
assays of the final 445 patients (all samples collected into
citrated tubes) were used to examine their relationship with
clinical outcomes. The protocol was approved by each
institution’s review board, and all patients gave written
informed consent.
Medications and treatment. Guidelines were provided for
adjunctive pharmacologic therapies, although the actual
selection of agents and dosing was according to institutional
practice and standards. Likewise, PCI with any FDA-
approved device was allowed provided the intent was to
place a stent at all target lesions. Aspirin (325 mg) was to be
given the morning of the procedure. Clopidogrel adminis-
tered either as a 300-mg loading dose on the day of the
procedure (before PCI) or 75 mg daily for four days before
the procedure was encouraged. The use and type of glyco-
protein (GP) IIb/IIIa inhibitor was left to the discretion of
the interventionalist. For patients receiving SC enoxaparin
and having received their last dose within 8 h of PCI, no
further enoxaparin was recommended. For patients who had
received their last dose between 8 and 12 h before PCI, a
0.3-mg/kg IV bolus of enoxaparin was suggested (3). These
guidelines were the same regardless of whether a patient
received a GP IIb/IIIa inhibitor. For patients not already
receiving SC enoxaparin, a 0.75-mg/kg IV bolus was to be
given immediately before PCI if receiving a GP IIb/IIIa
inhibitor during the procedure. For patients not already
receiving SC enoxaparin and not receiving a GP IIb/IIIa
inhibitor during PCI, a 1.0-mg/kg IV bolus of enoxaparin
was to be given.
At the conclusion of PCI, an arteriotomy closure device
could be used according to local practice. Otherwise sheaths
were to be removed 4 h after the last bolus administration of
IV enoxaparin. For patients receiving only SC enoxaparin,
sheaths were to be removed 6 to 8 h following the last SC
dose. For patients who received SC heparin with an
additional pre-procedural dose (0.3 mg/kg) given intrave-
nously, the sheath was recommended to be removed 4 to 6 h
after the IV booster dose.
Blood samples. For patients receiving SC enoxaparin
without an IV supplement, a sample was collected imme-
diately prior to PCI. For patients receiving SC enoxaparin
and an IV supplement, a sample was collected before and
after the IV bolus. For patients treated only with IV bolus
enoxaparin, a sample was collected 5 to 10 min after the
bolus. Whole blood samples were obtained from the femoral
arterial sheath (after first discarding 3 ml of blood) and
placed into a 3.2% sodium citrated tube (2.7 ml). Immedi-
ately upon collection, the samples were tested in duplicate
with the ENOX test card. The remaining citrated blood was
centrifuged, and the resulting plasma was aliquoted in
cryovials and frozen at 70°C. The anti-Xa concentrations
in the archived plasma samples were determined in a central
coagulation core laboratory.
Assays. The Rapidpoint Coag system consists of a
microprocessor-based analyzer and single-use assay-specific
test cards (Fig. 1). The Rapidpoint photo-mechanically
monitors fibrin clot formation in a flat capillary chamber on
the surface of a test card. After the test card is inserted into
the reader, it is warmed to 37°C, and the operator adds a
single drop of citrated whole blood to the sample well. As
blood is drawn into the reaction chamber, the reagents are
re-hydrated, and paramagnetic iron particles are stimulated
to move in the test chamber by an oscillating magnetic field.
Within the blood sample, Factor Xa is rapidly produced by
a specific Factor X activator, thereby initiating the clotting
cascade. As a clot begins to form, fibrin strands attach
themselves to the iron particles, impeding their movement.
Particle movement is monitored by an infrared optical
system, and a preset reduction in particle movement signals
the test’s end point. Enoxaparin from the patient’s blood
complexes with antithrombin to inhibit Factor Xa (and to a
lesser extent Factor IIa) and proportionally lengthens the
clotting time. The ENOX card is optimized for enoxaparin
monitoring, but is affected by other heparins. The ENOX
times are not affected by thienopyridines or GP IIb/IIIa
inhibitors. Among 120 normal volunteers, ENOX times
ranged from 106 to 160 s (mean  2 SD), and among 166
unanticoagulated patients citrated blood samples ranged
from 70 to 180 s (mean  2 SD). The correlation between
ENOX times and measured plasma anti-Xa levels is high
Abbreviations and Acronyms
ACS  acute coronary syndrome
ACT  activated clotting time
FDA  Food and Drug Administration
GP  glycoprotein
IV  intravenous
LMWH  low-molecular-weight heparin
MI  myocardial infarction
PCI  percutaneous coronary intervention
SC  subcutaneous
TIMI  Thrombolysis In Myocardial Infarction
TVR  target vessel revascularization
UFH  unfractionated heparin
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(r  0.88), with a value of 260 s approximating a plasma
anti-Xa level of 1.0 IU/ml (2).
The frozen plasma samples were sent to a central coag-
ulation core laboratory (Hemostasis Reference Laboratory,
Henderson Research Centre, Hamilton, Ontario) for
batched anti-Xa analysis. The plasma levels of enoxaparin
were assessed by measurement of the anti-Xa activity using
the amidolytic method with a chromogenic substrate (Sta-
chrom Heparin assay [Diagnostica Stago, Asnieres-Sur-
Seine, France] and the AMAX 190 instrument [Heinrich
Amelung, Lemgo, Germany]) (4).
End points and statistics. Clinical and procedural data
were prospectively entered onto case report forms specific
for this trial. Samples for cardiac marker assays (creatine
kinase and its MB fraction) were obtained at 8, 16, and 24 h
post-PCI or until hospital discharge, whichever occurred
first. Clinical outcomes including bleeding complications
were assessed to seven days or hospital discharge, whichever
occurred first. Periprocedural MI was defined as the devel-
opment of new Q waves after PCI in two or more
contiguous leads or a 3-fold elevation in the creatine
kinase or its MB fraction in one sample. Major bleeding was
defined according to the Thrombolysis In Myocardial In-
farction (TIMI) criteria and included a hemoglobin drop
5 g/dl or intracranial hemorrhage. Minor bleeding was
defined according to the TIMI criteria and included a blood
loss between 3 and 5 g/dl with a known bleeding site or a
loss of 3 g/dl associated with gross hematuria, hemate-
mesis, or hemoptysis (5). Any bleeding, by study definition,
included the above plus the occurrence of access site
complications including hematoma 5 cm, significant re-
bleeding after initially achieving hemostasis, or bleeding
delaying hospital discharge.
Descriptive statistics included demographic, medication,
laboratory, and procedural details, as well as ENOX times,
anti-Xa activity levels, and clinical events. For continuous
variables, mean ( SD) and median (25th, 75th percentile)
values were determined. For categorical variables, percent-
ages were calculated, and comparisons were performed with
a chi-squared test. To explore outcome relationships, scatter
plots with kernel regression curves (6) were created for the
composite ischemic end point versus procedural ENOX
times and for any bleeding event versus pre-sheath removal
ENOX times. Logistic regression was used to model the
relationship between probability of an outcome and the
natural log of the ENOX time. The modeling of the
dose-response relationships between the Rapidpoint ci-
trated ENOX time and reference laboratory assessments of
anti-Xa activity was performed using the standard Emax
curve (7) estimated within the nonlinear mixed effect model
framework. A 0.05 level was used to test statistical signifi-
cance.
RESULTS
From February 2002 to September 2002, a total of 673
patients were enrolled at 15 U.S. medical centers (see online
Appendix, which can be found at http://www.cardiosource.
com/jacc.html). Patient demographics for the final 445
patients are listed in Table 1. The cohort was 69% male, an
average age of 63 years, and 52% had a primary diagnosis of
unstable angina or recent MI. All patients received enox-
aparin, and 75% received a concomitant GP IIb/IIIa inhib-
itor. During the time of the study it was separately appre-
ciated that precision with ENOX samples collected into
citrated tubes was greater than that with non-citrated
samples, and this sample type became FDA approved for
the assay (2). Therefore, the final Evaluating Enoxaparin
Clotting Times (ELECT) study analyses were performed
using data from the last 445 patients, all of who had citrated
samples collected. The baseline characteristics of these
patients were similar to the overall cohort. The routes of
Figure 1. The Rapidpoint ENOX coagulation monitor card technology. Within the device an oscillating magnet moves the paramagnetic iron oxide
particles (PIOP) on the card once the dry reagent dissolves from the added whole blood. After Factor Xa activation, coagulation occurs and the reduced
motion of the iron particles is detected by a change in reflected infrared light.
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enoxaparin administration and concomitant use of GP
IIb/IIIa agents among patients are depicted in Figure 2.
The two groups of patients receiving SC enoxaparin (i.e.,
with and without a GP IIb/IIIa inhibitor) were combined
for analysis as only two patients received enoxaparin subcu-
taneously without a GP IIb/IIIa inhibitor. The three enox-
aparin dosing strategies: 1) 1.0 mg/kg subcutaneously twice
daily, 2) 0.75 mg/kg single IV bolus with a GP IIb/IIIa
inhibitor, or 3) 1.0 mg/kg IV bolus without a GP IIb/IIIa
inhibitor, corresponded to 8%, 68%, and 24% of the final
study group, respectively. Procedure-related details are
listed in Table 2.
ENOX times and anti-Xa levels. The Emax relationship
between ENOX times and central laboratory anti-Xa levels
was moderate (Fig. 3) (r  0.75), and values for the various
collection times are listed in Table 3. Among patients
receiving SC enoxaparin for an ACS, the respective median
ENOX times and anti-Xa levels were 208 s and 0.9 IU/ml
upon arrival at the catheterization laboratory. After a
0.3-mg/kg enoxaparin supplemental bolus for patients
whose last SC dose was between 8 to 12 h earlier, the
median ENOX time and anti-Xa level increased to 257 s
and 1.4 IU/ml, respectively. The procedural ENOX times
for those receiving a 0.75 and 1.0 mg/kg single IV bolus of
enoxaparin were 412 and 433 s, and these corresponded to
anti-Xa levels of 1.5 and 1.9 IU/ml, respectively. At the
time of sheath removal, the overall group’s median ENOX
and anti-Xa levels decreased to 239 s and 0.8 IU/ml; both
results were approximately 40% to 50% lower among those
whose sheath was removed several hours after the procedure
as compared with those whose sheath was removed imme-
diately after PCI and an arteriotomy closure device was
used.
Clinical outcomes. Overall ischemic and hemorrhagic
event rates were low (Table 4) with an in-hospital compos-
ite of death, MI, and urgent target vessel revascularization
(TVR) occurring in 5.4% of patients. This ischemic com-
posite, as in many contemporary PCI-stent trials, was
largely comprised (87%) of procedure-associated MI, as
death and urgent TVR occurred in 1% of patients. TIMI
major and minor bleeding episodes were observed in 0.2%
and 1.3% of patients, respectively. “Any bleeding” occurred
in 7.9% of patients. Transfusions were needed in only 1.3%
of patients, and the bleeding index was 0.7  1.2.
Relationship of ENOX times with adverse events. The
mean procedural ENOX time for patients with and without
an ischemic event was similar (461 and 429 s, respectively).
A kernel regression curve plotting ENOX times versus
ischemic events (Fig. 4) shows a nadir event rate at
approximately 300 to 350 s; however, using a logistic
regression model, no significant association between isch-
emic events and ENOX times was observed (p  0.222).
The average ENOX value prior to sheath removal was 303 s
among those with any bleeding event versus 266 s among
those without bleeding. The kernel regression curve plotting
ENOX values versus any bleeding shows increasing bleed-
ing with increasing ENOX values over most of the clotting
time range (Fig. 5), and the positive slope effect for the
regression model was significant (p  0.010).
Among the 445 patients studied with citrated samples, 2
patients died. One patient was a 78-year-old woman un-
dergoing right coronary artery PCI who was given IV
enoxaparin and abciximab. The procedure required exten-
sive stent placement for threatened vessel closure and was
complicated by dissection into the ascending aorta. The
procedural ENOX time was low (177 s), and it was
speculated the IV catheter became infiltrated into the SC
tissue before enoxaparin administration. The second patient
was a 63-year-old man who had been treated for two days
with IV eptifibatide and twice daily SC enoxaparin for a
non–Q-wave MI. During PCI of a saphenous vein bypass
graft, abrupt closure occurred. The patient had a moderate-
sized infarction and subsequently expired. The blinded
procedural ENOX time was 163 s, and it was discovered
that the patient had inadvertently not received the morning
dose of enoxaparin before being transferred to the catheter-
ization laboratory.
Figure 2. Distribution of patients enrolled in ELECT according to
anticoagulation received. GP  glycoprotein; IV  intravenous; PCI 
percutaneous coronary intervention; Rx  treatment; SC  subcutaneous.
Table 1. Baseline Characteristics
Characteristics
Patients With Citrated
Samples (N  445)
Age (yrs) 63.4
Male 69.0
Caucasian 89.7
Hypertension 67.8
Diabetes 32.9
Hypercholesterolemia 62.7
Recent ACS 51.8
Peripheral vascular disease 6.3
Previous MI 33.1
Previous PCI 41.0
Previous CABG 16.0
All data are percentages except where listed.
ACS  acute coronary syndrome (unstable angina or myocardial infarction);
CABG  coronary artery bypass grafting; MI  myocardial infarction; PCI 
percutaneous coronary intervention.
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DISCUSSION
During PCI, the most commonly used anti-thrombin agent
remains UFH. This heterogeneous agent has many known
limitations, and LMWH and direct thrombin inhibitors
have shown equivalence or superiority over UFH in several
PCI trials (8–10). Conversely, the volume of experience
with UFH and its monitoring with the ACT is extensive.
Cited concerns regarding use of enoxaparin as a primary
anticoagulant for PCI or for bridging upstream enoxaparin
with its use in the catheterization laboratory include the
inability to rapidly monitor its activity (3). Because enox-
aparin contains various chain lengths, it too produces a
several-fold range of anticoagulation among patients, al-
though to a lesser degree than UFH. Our study is the first
to systematically assess a rapid, point-of-care enoxaparin
monitor during PCI and to correlate these results with
clinical outcome.
Our observation that periprocedural ischemic event rates
are low (5.4%) and not clearly linked to the measured extent
of LMWH anticoagulation in the GP IIb/IIIa era comple-
ment the findings of Chew et al. (11) who demonstrated a
relatively flat dose-response relationship between ACT and
ischemic events among 3,876 patients receiving UFH with
GP IIb/IIIa inhibitors and of Tolleson et al. (12), who
observed similar findings in the 2,064-patient Enhanced
Suppression of the Platelet IIb/IIIa Receptor with Integrilin
Therapy (ESPRIT) study. The suggestion of a U-shaped
event curve has been reported by others relating level of
anticoagulation to outcome events during ACS and PCI
(11,13). Considering enoxaparin specifically, observational
PCI studies, such as National Investigators Collaborating
on Enoxaparin (NICE)-1 and NICE-4, and more recently
studies by Choussat et al. (17) and Carnendran et al. (18),
have tested progressively lower doses of IV enoxaparin (1.0,
Figure 3. Correlation of ENOX times with anti-Xa levels in the ELECT study. The ENOX test card reports clotting times to a maximum of 700 s.
Table 2. Procedural Details
Characteristics
SC Enoxaparin  GP IIb/IIIa
(n  33)
IV Enoxaparin  GP IIb/IIIa
(n  305)
IV Enoxaparin  GP IIb/IIIa
(n  107)
All Patients
(N  445)
LVEF (%) 52  11 53  12 52  10 53  11
2 target lesions 45.5 39.1 45.3 41.1
LAD 24.2 40.4 44.4 40.4
LCX 15.1 26.5 23.6 24.9
RCA 57.6 27.5 28.3 29.9
SVG 3.1 5.3 1.9 4.3
Bailout therapy* 9.1 3.6 12.1 6.1
Vessel closure† 6.1 0.3 0 0.7
Final TIMI 3 flow 100 99 100 99
Closure device 63.6 36.2 16.0 33.4
Angioseal 52 52 12 47
Perclose 43 38 82 44
Vasoseal 0 10 0 7
Other 5 0 6 2
All data are percentages where listed. *Bailout therapy was additional procedural heparin for threatened or abrupt closure or unplanned administration of a glycoprotein IIb/IIIa
inhibitor. †Vessel closure was defined as abrupt closure or no reflow following PCI.
GP glycoprotein; IV intravenous; LAD left anterior descending artery; LCX left circumflex artery; LVEF left ventricular ejection fraction; RCA right coronary
artery; SC  subcutaneous; SVG  saphenous vein graft; TIMI  Thromobolysis in Myocardial Infarction.
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0.75, and 0.5 mg/kg, respectively) over time (14–18).
Although these studies differed regarding design, patient
cohort, devices, and GP IIb/IIIa inhibitor use, it is note-
worthy that both the 30-day ischemic event rates and major
plus minor bleeding rates have steadily declined (Table 5).
This pattern of trial results also suggests that the extent of
anticoagulation may not be tightly linked to ischemic events
among contemporary stent GP IIb/IIIa procedures or that
other factors are relatively more important.
Bleeding from a “relative excess” of anticoagulation has
been observed with virtually all anticoagulants, and in most
cases the bleeding dose-response is positive and linear. In
the present study with enoxaparin, the kernel smoothing
plot shows a 1% increase in any bleeding for every 30 s
increase in ENOX time (Fig. 5). Although these events
were primarily nuisance bleeding, such as groin hematoma,
they were predictable and frequent at higher ENOX times.
As the ENOX time prior to sheath removal decreased to
under 200 s, the composite bleeding event rate fell below
5%. Also unique to our study was the use of arteriotomy
closure devices; prior enoxaparin-in-PCI studies have pre-
cluded their use. Although the use of closure devices was not
randomized in the ELECT study, we observed a greater
than doubling in the rate of any bleeding events with
closure devices as compared with manual compression
(12.2% vs. 5.7%). As expected, patients receiving a
closure device had higher ENOX times at the time of
sheath removal (Table 3).
Optimal ENOX time range. A key goal of this study was
to gain insight regarding an optimal procedural ENOX time
for performing PCI and a level for safe arterial sheath
removal. Although no statistically significant association
was found between ENOX times and ischemic events, we
made several observations: 1) a nadir of ischemic events did
appear to be present between 300 to 350 s; 2) both ischemic
and bleeding events rates appeared to be unacceptably high
both in our dataset and in prior observations (14,15,19)
(Table 5) once the ENOX time exceeded 450 s or the
anti-Xa level exceeded 1.8 IU/ml; and 3) the overwhelming
majority of patients receiving either SC or IV enoxaparin
had procedural ENOX values 250 s. Based on these
conditions, we made a single post hoc analysis separating
patients into two groups according to whether or not the
procedural ENOX clotting time was between 250 to 450 s.
The ischemic composite of death, MI, and urgent TVR
occurred in 4.0% of patients within the suggested procedural
ENOX range versus 7.2% (p  0.134) among those whose
values were 250 or 450 s.
The safety of arterial sheath removal is affected by several
unrelated factors such as underlying peripheral vascular
Table 3. Anti-Xa Levels and ENOX Times
Characteristics
SC Enoxaparin  GP IIb/IIIa
(n  33)
IV Enoxaparin  GP IIb/IIIa
(n  305)
IV Enoxaparin  GP IIb/IIIa
(n  107)
All Patients
(N  445)
Anti-Xa (IU/ml)
Pre-procedural 0.9 (0.6, 1.2)
Procedural 1.4 (1.0, 1.6) 1.5 (1.3, 1.7) 1.9 (1.7, 2.1) 1.6 (1.4, 1.9)
Sheath removal 1.0 (0.8, 1.2) 0.8 (0.5, 1.2) 0.8 (0.6, 1.1) 0.8 (0.6, 1.2)
Closure device 1.0 (0.8, 1.3) 1.3 (1.0, 1.5) 1.5 (1.4, 1.7) 1.3 (1.0, 1.5)
Manual compression 1.0 (0.9, 1.0) 0.6 (0.5, 0.8) 0.8 (0.6, 1.0) 0.6 (0.5, 0.9)
ENOX time (s)
Pre-procedural 208 (164, 319)
Procedural 257 (200, 340) 412 (354, 514) 433 (384, 513) 414 (356, 511)
Sheath removal 238 (196, 305) 239 (185, 329) 232 (203, 305) 239 (190, 319)
Closure device 268 (213, 310) 370 (316, 435) 381 (337, 446) 364 (309, 433)
Manual compression 224 (194, 242) 199 (173, 239) 222 (192, 258) 207 (178, 244)
Data are median (25th, 75th percentile).
GP  glycoprotein; IV  intravenous; SC  subcutaneous.
Table 4. Outcomes
Event (%)
SC Enoxaparin  GP IIb/IIIa
(n  33)
IV Enoxaparin  GP IIb/IIIa
(n  305)
IV Enoxaparin  GP IIb/IIIa
(n  107)
All Patients
(N  445)
MACE composite 6.1 5.6 4.7 5.4
Death 3.0 0.3 0 0.4
Myocardial infarction 6.1 4.6 4.7 4.7
Urgent TVR 0 0.7 0 0.4
TIMI major bleeding 0 0 0.9 0.2
TIMI minor bleeding 6.1 1.0 0.9 1.3
Any bleeding* 18.2 8.5 2.8 7.9
Bleeding index (g/dl) 1.2  1.1 0.7  1.2 0.6  1.1 0.7  1.2
All data are percentages except where listed. *Any bleeding is a composite of TIMI major and minor bleeding, access site re-bleeding after initial hemostasis, hematoma 5 cm
and bleeding prolonging hospital stay; bleeding index is the change in hemoglobin corrected for transfusions.
GP  glycoprotein; IV  intravenous; MACE  major adverse cardiac events, and composite included all-cause mortality, myocardial infarction, and urgent repeat
revascularization; SC  subcutaneous; TIMI  Thrombolysis In Myocardial Infarction; TVR  target vessel revascularization.
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disease, sheath size, duration of sheath dwelling, and extent
of anticoagulation. Because bleeding rates were directly
correlated with ENOX times, it is intuitive that lower
ENOX times are desirable prior to sheath removal, yet
delayed sheath removal increases the risk of vascular com-
plications. Therefore, we propose sheath removal once the
ENOX time is within the 200 to 250 s range guided by the
clinical scenario. This ENOX range corresponds to anti-Xa
levels of 0.6 to 0.8 IU/ml and begins to approach 2 SDs
beyond the upper limit of normal for unanticoagulated
patients (180 s). For patients at increased bleeding risk (e.g.,
concomitant GP IIb/IIIa therapy, larger sheath size, pres-
ence of peripheral vascular disease) the ENOX time should
be closer to 200 s; whereas those at lower risk can likely have
safe sheath removal at values nearer 250 s.
Study limitations. There are several limitations to our
study that are primarily related to the sample size and the
relatively low rates of ischemic and bleeding events. Given
the small number of adverse events, it was not possible to
correlate major clinical outcomes with ENOX times. Al-
though an apparent pattern emerged for ischemic events
and a significant pattern for all bleeding events, further
studies will be needed to test the optimal ENOX time
regarding clinical outcome. The targeted anti-Xa range of
0.8 to 1.8 IU/ml must be considered somewhat arbitrary as
no prospective study has been performed. This range was
based upon prior and current observations and upon the
American College of Chest Physicians’ consensus guidelines
to have anti-Xa levels 0.6 IU/ml for medical therapy
(19,20). Finally, we did not enroll patients with acute MI, so
that further study will be needed for both these and
higher-risk patients.
Conclusions. In this enoxaparin-in-PCI study, ischemic
events were infrequent although lower in the mid-range of
ENOX times measured. Bleeding events were primarily
limited to the access site and were more common with
increasing ENOX times. These observations, combined
with suggested procedural anti-Xa levels of 0.8 to 1.8
IU/ml, translate into a recommended ENOX range of 250
to 450 s for PCI and 200 to 250 s for safe arterial sheath
removal. Ongoing and future studies will be able to assess
the clinical relevance of ENOX times during partial enox-
aparin reversal with protamine and to discern whether
booster doses of enoxaparin for “sub-therapeutic” anticoag-
ulation are helpful or needed.
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Figure 5. Kernel smoothing regression and 95% confidence interval lines
assessing the occurrence of any bleeding event over the range of ENOX
times prior to sheath removal. For display purposes, several ENOX values
200 were truncated at 200 and several 600 were truncated at 600.
Table 5. Anti-Xa Levels and Clinical Events in Observational Enoxaparin-PCI Trials
Study N Dose
Anti-Xa
5 Min
Anti-Xa
15 Min
30-Day
Ischemic
MACE
Anti-Xa
4 h
Major
Bleeding
Minor
Bleeding Transfuse
NICE-1 (14) 828 1.0 mg/kg IV  1 2.1  0.7 1.9  0.6 7.7% 0.8  0.3 1.1% 6.2% 2.7%
NICE-4 (15) 818 0.75 mg/kg IV  1  abx 1.7  0.9 1.5  0.5 6.8% 0.6  0.3 0.4% 7.0% 1.8%
Collet et al. (16) 293 1.0 mg/kg SC  4 1.0  0.2 3.0% 0.8% 2.4%
Choussat et al. (17) 242 0.5 mg/kg IV  1  integ 0.9  0.3 2.5% 0.5  0.2 0.4% 1.2%
ELECT 445 All groups 1.6  0.8 5.4% 0.7  0.3 0.3% 1.3% 1.3%
Anti-Xa levels (IU/ml) are mean  1 SD.
abx  abciximab; ELECT  Evaluating Enoxaparin Clotting Times; integ  integrilin; IV  intravenous; MACE  major adverse cardiac events, and composite included
all-cause mortality, myocardial infarction, and urgent repeat revascularization; NICE  National Investigators Collaborating on Enoxaparin; PCI  percutaneous coronary
intervention; SC  subcutaneous.
Figure 4. Kernel smoothing regression and 95% confidence interval lines
assessing the occurrence of major adverse cardiac events (MACE) over the
range of procedural ENOX times. For display purposes, several ENOX
values200 were truncated at 200 and several600 were truncated at 600.
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APPENDIX
Participating centers and coordinators: Cleveland Clinic:
P. Welsh, R. Bartow, G. McConnell; Duke University: C.
Martz, P. Gottlieb, E. Yow, V. Hasselblad, D. Joseph, K.
Raffetto, S. Wu, M. Roe; Forsythe Hospital: S. Key, J.
Stone; Genesis Heart Institute: V. Takes; Houston VAMC:
N. Hinton-Davis; Lindner Center: M. Mueller; Baylor
College of Medicine: K. Maresch; Riverside Methodist
Hospital: P. Vieira; Norfolk General: N. Sullivan; St.
Vincent’s Hospital: L. Burkert; University of Massachu-
setts: S. Ball; University Hospital of Cleveland: L. Hickel;
Wake Forest University: T. Young; Wake Heart Associates:
F. Wood; William Beaumont Hospital: S. Didocha; Mayo
Clinic: P. Berger.
For a list of the medical centers, investigators, and
research coordinators who participated in ELECT, please
see the September 17, 2003, issue of JACC at http://
www.cardiosource.com/jacc.html.
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